Relmada Therapeutics (RLMD) Stock Price, News & Analysis

Company Overview

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system disorders. The company’s research has primarily centered on treatments for depression and other conditions involving the brain and nervous system.

Relmada’s lead investigational product is REL-1017, also known as esmethadone or dextromethadone. The orally administered compound is being studied as a potential treatment for major depressive disorder and is designed to modulate the N-methyl-D-aspartate (NMDA) receptor. REL-1017 has been evaluated in clinical studies as a possible therapy for patients who do not respond adequately to existing antidepressants.

Founded in 2004, Relmada has conducted its clinical development activities primarily in the United States and other international research locations. The company is headquartered in the United States and is led by Sergio Traversa, who serves as chief executive officer. Relmada’s progress and business outlook depend largely on the continued development, regulatory review and potential commercialization of its investigational therapies.

Key Stats

• Today's Range: $3.65 to $3.76
• 50-Day Range: $3.73 to $5.47
• 52-Week Range: $1.80 to $8.00
• Volume: 321,380 shs
• Average Volume: 1.48 million shs
• Market Capitalization: $397.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Moderate Buy

Relmada Therapeutics Stock Analysis - MarketRank™

Relmada Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 371st out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Relmada Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 5 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Relmada Therapeutics has a consensus price target of $12.00, representing about 218.3% upside from its current price of $3.77.

Amount of Analyst Coverage

Relmada Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Relmada Therapeutics are expected to decrease in the coming year, from ($0.62) to ($0.78) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Relmada Therapeutics is -4.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Relmada Therapeutics is -4.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Relmada Therapeutics has a P/B Ratio of 3.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.86% of the float of Relmada Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Relmada Therapeutics has a short interest ratio ("days to cover") of 9.25.

Change versus previous month

Short interest in Relmada Therapeutics has recently increased by 6.33%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Relmada Therapeutics does not currently pay a dividend.

Dividend Growth

Relmada Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.81

News Sentiment

Relmada Therapeutics has a news sentiment score of 1.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Relmada Therapeutics this week, compared to 2 articles on an average week.

MarketBeat Follows

2 people have added Relmada Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 3.9 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $843,990.00 in company stock, which represents 0.2099% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Relmada Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $843,990.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

14.50% of the stock of Relmada Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

45.24% of the stock of Relmada Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/01/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:RLMD
• CIK: 1553643
• Web: www.relmada.com
• Phone: (786) 629-1376
• Fax: N/A
• Employees: 17
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Relmada Therapeutics: $12.00
• High Price Target: $19.00
• Low Price Target: $8.00
• Potential Upside/Downside: +224.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$57.38 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -47.52%
• Return on Assets: -43.97%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 29.52
• Quick Ratio: 29.52

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.18 per share
• Price / Book: 3.13

Miscellaneous

• Outstanding Shares: 106,670,000
• Free Float: 91,203,000
• Market Cap: $394.15 million
• Optionable: Optionable
• Beta: 0.45